Avanzanite Bioscience
Avanzanite Bioscience is a biopharmaceutical company that commercializes orphan medicines in Europe, with 90 employees and $37M in Series A funding led by MVM Life Science Partners.
The growth story
Avanzanite Bioscience grew from 11 to 90 employees between 2022 and 2026, raising $37M along the way, most recently a Series A in November 2025.
About
Avanzanite partners with biopharmaceutical firms to bring rare disease treatments to European markets. The company focuses on both commercializing orphan drugs and improving patient access, leveraging its team's decades of industry experience.
The firm has grown to 90 employees since its 2021 founding, with its Series A round closing in late 2025. Its workforce comes primarily from major pharma companies like Amgen and Novartis.
Founders and leadership
Sales is the largest function at Avanzanite, with 8 employees. The company was founded by biopharmaceutical executives Adam Plich and Anant Murthy, who lead its Amsterdam-based operations.
The Avanzanite Bioscience org chart
Adam Andrzej Plich (Co-Founder & CEO) leads 60 mapped leaders with 3 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Sales 25 (+150% YoY), Healthcare Services 16 (+300% YoY), Operations 11 (+38% YoY), Business Development 6 (+50% YoY), Research 5 (+67% YoY), Administrative 4 (+300% YoY).
Talent flow
Avanzanite's team comes mainly from large pharmaceutical firms, with Amgen (11), Novartis (9) and GSK (8) being top sources. Employee tenure averages just one year, suggesting rapid turnover or recent hiring surges.
Most common previous employers of Avanzanite Bioscience staff: Amgen (11), Novartis (9), GSK (8), Pfizer (7), Teva Pharmaceuticals (6), Amicus Therapeutics (6). Former Avanzanite Bioscience employees most often moved to SUN PHARMA (1), Incyte (1), PharmArrow (1), PharmaBase (1), Avanzanite Bioscience (1), BridgeBio (1).
What this company is made of
Most common skills at Avanzanite Bioscience: Pharmaceutics (46), Product Launch (34), Oncology (33), Pharmaceutical Sales (30), Biotechnology (30), Market Access (27), Marketing Strategy (25), Management (24).
Where the team actually sits
Avanzanite Bioscience people are concentrated in England, United Kingdom (6), Bavaria, Germany (5), North Holland, Netherlands (4), Greece (4).
Search footprint
Avanzanite Bioscience attracts about 9 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 4 ranking keywords and lost 2 in the last period.
Frequently asked
Avanzanite Bioscience has 90 employees as of September 2026.
Avanzanite Bioscience has raised $37M in total, most recently a Series A round in November 2025.
Avanzanite Bioscience was founded in 2021 by Adam Andrzej Plich, Anant Murthy.
Adam Andrzej Plich (Co-Founder & CEO) sits at the top of Avanzanite Bioscience's reporting structure, with 3 direct reports.
The most common previous employers of current Avanzanite Bioscience staff are Amgen (11 people), Novartis (9 people), GSK (8 people).
Former Avanzanite Bioscience employees most often move to SUN PHARMA (1), Incyte (1), PharmArrow (1).
Avanzanite Bioscience attracts about 9 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Avanzanite Bioscience staff are Pharmaceutics, Product Launch, Oncology, Pharmaceutical Sales, Biotechnology.
Avanzanite Bioscience staff are concentrated in England, United Kingdom (6), Bavaria, Germany (5), North Holland, Netherlands (4).
Avanzanite Bioscience has about 25 people in Sales, up 150% over the past year, as of September 2026.
Avanzanite Bioscience has about 16 people in Healthcare Services, up 300% over the past year, as of September 2026.
Computed from 68 current and 8 former Avanzanite Bioscience profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.